Top Story

Secondary analysis of DRCR.net Protocol T compares improvement and worsening rates over 2 years

April 27, 2017

A secondary analysis of DRCR.net Protocol T data demonstrated significant, sustained improvement rates of both nonproliferative and proliferative diabetic retinopathy at 1 and 2 years with all three anti-VEGF agents, low rates of worsening and relatively better performance of aflibercept.

A total of 650 participants were analyzed, 495 with nonproliferative DR and 155 with proliferative DR. Both groups were reduced in number during the course of the study to comply with the study criteria. Improvement and worsening at 1 and 2 years were evaluated by fundus photography according to ETDRS classification levels.

Avedro secures $42 million in funding, opens manufacturing facility

April 27, 2017
Avedro has secured $42 million in equity and debt financing to commercially expand and develop its product pipeline, the company announced in a press release. Led by…
In the Journals

Study finds high prevalence of undiagnosed AMD in primary eye care

April 27, 2017
A study found a high rate of undiagnosed age-related macular degeneration in primary eye care practices and advocated the need for improved detection strategies…

BLOG: Integrating visual electrophysiology into a practice

April 27, 2017
One of the issues faced by ophthalmologists is knowing which new technology should be incorporated into our practices. Because technological advances happen quickly, it…
In the Journals

Genetic testing may give molecular diagnoses in pediatric inherited retinal disease cases

April 26, 2017
In a retrospective case series, a majority of children with inherited retinal disease who underwent genetic testing were found to have a probable or possible molecular…
More News Headlines »
Clinical Science

Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration

Ophthalmic Surgery, Lasers and Imaging Retina, April 2017, Volume 48 Issue 4
The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular…
More »

Inflamed and Untamed: Managing the Progression of Diabetic Eye Disease

This activity is supported by an educational grant from Allergan, Inc.

Diabetic retinopathy (DR) is a major cause of blindness, with an estimated 4.2 million people over the age of 40…
More »
Meeting News

VIDEO: Expert identifies new ways to improve profitability

March 2, 2017
More »